Seeking Alpha

Hemispherx Biopharma (HEB -21.2%) gets slammed today after saying the FDA's Arthritis Advisory...

Hemispherx Biopharma (HEB -21.2%) gets slammed today after saying the FDA's Arthritis Advisory Committee has shot down its New Drug Application for the marketing of Ampligen for chronic fatigue syndrome by a 9-4 vote, with one abstention. The agency said that, considering the totality of the data, there wasn't sufficient evidence of Ampligen's safety or treatment efficacy.
Comments (1)
  • vmsh72
    , contributor
    Comments (2) | Send Message
     
    if it doesn't move up..i lost my whole money...long!!!
    23 Dec 2012, 04:29 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs